Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 12, 2024

BUY
$0.68 - $1.31 $37,290 - $71,839
54,839 Added 294.98%
73,430 $64,000
Q3 2023

Oct 13, 2023

BUY
$1.14 - $1.81 $4,244 - $6,738
3,723 Added 25.04%
18,591 $25,000
Q2 2023

Jul 10, 2023

SELL
$1.79 - $4.59 $37,582 - $96,371
-20,996 Reduced 58.54%
14,868 $27,000
Q1 2023

Apr 28, 2023

BUY
$2.84 - $3.92 $101,853 - $140,586
35,864 New
35,864 $140,000
Q3 2022

Oct 31, 2022

SELL
$4.08 - $5.82 $310,157 - $442,430
-76,019 Reduced 83.32%
15,214 $83,000
Q2 2022

Jul 29, 2022

BUY
$4.15 - $8.37 $378,616 - $763,620
91,233 New
91,233 $411,000
Q1 2022

Apr 29, 2022

SELL
$5.91 - $14.38 $140,161 - $341,036
-23,716 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$5.21 - $8.61 $96,296 - $159,138
-18,483 Reduced 43.8%
23,716 $152,000
Q3 2021

Nov 01, 2021

BUY
$4.45 - $10.63 $187,785 - $448,575
42,199 New
42,199 $246,000
Q2 2021

Aug 12, 2021

SELL
$8.11 - $11.11 $131,941 - $180,748
-16,269 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$9.85 - $17.69 $160,249 - $287,798
16,269 New
16,269 $171,000
Q4 2020

Feb 04, 2021

SELL
$14.15 - $17.19 $903,689 - $1.1 Million
-63,865 Closed
0 $0
Q3 2020

Nov 09, 2020

BUY
$14.14 - $19.71 $608,232 - $847,825
43,015 Added 206.31%
63,865 $932,000
Q2 2020

Jul 20, 2020

BUY
$16.6 - $25.25 $145,681 - $221,594
8,776 Added 72.69%
20,850 $395,000
Q1 2020

Apr 30, 2020

BUY
$14.38 - $27.72 $48,244 - $93,000
3,355 Added 38.48%
12,074 $232,000
Q4 2019

Jan 28, 2020

BUY
$9.23 - $19.67 $80,476 - $171,502
8,719 New
8,719 $167,000
Q1 2018

May 03, 2018

SELL
$9.92 - $17.25 $100,132 - $174,121
-10,094 Closed
0 $0
Q4 2017

Jan 24, 2018

SELL
$9.15 - $11.99 $27,651 - $36,233
-3,022 Reduced 23.04%
10,094 $97,000
Q3 2017

Nov 07, 2017

BUY
$8.15 - $11.16 $106,895 - $146,374
13,116
13,116 $144,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $53.5M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.